Core Viewpoint - The West Pharmaceutical Services, Inc. is facing a class action lawsuit alleging violations of the Securities Exchange Act of 1934, with claims of misleading statements and operational inefficiencies impacting financial performance [1][3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled New England Teamsters Pension Fund v. West Pharmaceutical Services, Inc., and covers purchasers of common stock between February 16, 2023, and February 12, 2025 [1]. - Investors have until July 7, 2025, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit alleges that West Pharmaceutical made false statements regarding customer demand and the performance of its high-margin products [3]. Group 2: Allegations Against West Pharmaceutical - The lawsuit claims that West Pharmaceutical was experiencing significant destocking in its High-Value Products portfolio, contrary to its public statements [3]. - The SmartDose device, which was expected to be a high-margin growth product, is alleged to have caused profit margin dilution due to operational inefficiencies [3]. - The company’s exit from continuous glucose monitoring contracts is cited as a risk stemming from margin pressures [3]. Group 3: Financial Impact and Stock Performance - On February 13, 2025, West Pharmaceutical issued a revenue forecast of $2.88 billion to $2.91 billion, which was significantly below market expectations [4]. - The disappointing guidance was attributed to the loss of two major customers transitioning to in-house manufacturing and the decision not to participate in future contracts [4]. - Following the announcement, West Pharmaceutical's stock price fell by more than 38% [4].

NEW YORK, May 9, 2025 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against West Pharmaceutical Services, Inc. ("West" or "the Company") (NYSE: WST) and certain of its officers.Class DefinitionThis lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired West se ...

NEW YORK, May 9, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc." or the "Company") (NYSE: WST) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of West Pharmaceutical Services, Inc. investors who were adversely affected by alleged securities fraud between February 16, 2023 and February 12, 2025. Follow the link below to get more information and be contacted by a membe ...

Core Viewpoint - A class action lawsuit has been filed against West Pharmaceutical Services, Inc. for allegedly making false statements and failing to disclose significant issues affecting its financial performance during the Class Period from February 16, 2023, to February 12, 2025 [1][3]. Group 1: Allegations of Misleading Statements - The lawsuit claims that West Pharmaceutical misrepresented its visibility into customer demand and attributed challenges to temporary COVID-related product destocking, while it was actually facing ongoing destocking in its High-Value Products portfolio [3]. - It is alleged that the SmartDose device, which was marketed as a high-margin growth product, negatively impacted profit margins due to operational inefficiencies [3]. - The lawsuit also points out that these margin pressures could lead to costly restructuring activities, including the company's exit from continuous glucose monitoring contracts with long-standing customers [3]. Group 2: Financial Forecast and Market Reaction - On February 13, 2025, West Pharmaceutical issued a revenue forecast for 2025 between $2.88 billion and $2.91 billion, which was significantly below market expectations [4]. - The disappointing guidance was attributed to challenges in Contract Manufacturing, including the loss of two major continuous glucose monitoring customers transitioning to in-house manufacturing [4]. - Following the announcement, West Pharmaceutical's stock price fell by more than 38% [4].

Core Viewpoint - A class action lawsuit has been filed against West Pharmaceutical Services, Inc. for alleged violations of securities laws, claiming the company made false and misleading statements regarding its financial health and product performance [1][4]. Group 1: Lawsuit Details - The lawsuit pertains to securities purchased between February 16, 2023, and February 12, 2025, during which investors are encouraged to participate before July 7, 2025 [2]. - The Schall Law Firm is representing investors and specializes in securities class action lawsuits [5]. Group 2: Allegations Against the Company - The complaint alleges that West Pharmaceutical Services misrepresented its visibility into customer demand while experiencing significant destocking in its High-Value Products portfolio [4]. - The SmartDose device, which was marketed as a high-margin product, reportedly diluted profit margins due to operational inefficiencies [4]. - The company faced increasing margin pressures, raising concerns about potential restructuring, including the possibility of exiting long-term contracts for continuous glucose monitoring [4].

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc." or the "Company") (NYSE: WST) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of West Pharmaceutical Services, Inc. investors who were adversely affected by alleged securities fraud between February 16, 2023 and February 12, 2025. Follow the link below to get more information and be contacted by a ...

Core Viewpoint - The West Pharmaceutical Services, Inc. is facing a class action lawsuit alleging violations of the Securities Exchange Act of 1934 due to misleading statements and operational inefficiencies that led to significant financial losses for investors during the specified class period [1][3]. Group 1: Allegations and Financial Impact - The lawsuit claims that West Pharmaceutical misrepresented its visibility into customer demand and failed to disclose ongoing destocking issues in its High-Value Products portfolio, which negatively impacted profit margins [3]. - The company’s SmartDose device, initially positioned as a high-margin growth product, was revealed to be dilutive to profit margins due to operational inefficiencies [3]. - On February 13, 2025, West Pharmaceutical issued a revenue forecast of $2.88 billion to $2.91 billion for 2025, which was significantly below market expectations, leading to a stock price drop of over 38% [4]. Group 2: Class Action Process - Investors who purchased West Pharmaceutical common stock during the class period have until July 7, 2025, to seek appointment as lead plaintiff in the class action lawsuit [1][5]. - The lead plaintiff will represent the interests of all class members and can select a law firm of their choice for litigation [5]. Group 3: Company Background - West Pharmaceutical designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products [2]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized as a leading firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [6].

NEW YORK, May 8, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of West Pharmaceutical Services, Inc. (NYSE: WST).Shareholders who purchased shares of WST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/west-pharmaceutical-services-inc-loss-submission-form/?id=147325&from=4 CLAS ...

SAN DIEGO, May 7, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired West Pharmaceutical Services, Inc. (NYSE: WST) common stock between February 16, 2023 and February 12, 2025. West is a medical supplies company that specializes in the development, manufacture, and distribution of elastomer-based supplies for the containment and administration of injectable drugs.For more information, submit a form, ...

Core Viewpoint - A securities class action lawsuit has been filed against West Pharmaceutical Services, Inc. for failing to disclose significant operational issues and misleading investors regarding the company's financial health during the class period from February 16, 2023, to February 12, 2025 [1] Group 1: Allegations Against the Company - The complaint alleges that the company did not disclose ongoing destocking issues in its high-margin High-Value Products portfolio, contrary to claims of strong visibility into customer demand [2] - It is claimed that the SmartDose device, positioned as a high-margin growth product, was actually dilutive to profit margins due to operational inefficiencies [2] - The margin pressures led to risks of costly restructuring activities, including the exit from continuous glucose monitoring contracts with long-standing customers [2] - Positive statements made by the company regarding its business and prospects were materially false or misleading [2] Group 2: Impact of Disclosures - The truth about the company's financial struggles was revealed on February 13, 2025, when it issued weak revenue and earnings forecasts for 2025 [3] - The company attributed its disappointing guidance to contract manufacturing headwinds and the loss of two major glucose monitoring customers transitioning to in-house manufacturing [3] - The SmartDose wearable injector devices were indicated to be margin-dilutive in 2025, prompting the company to consider various options to improve its economics [3] - Following these disclosures, the company's stock price fell by $123.17 per share, a decline of 38%, closing at $199.11 on February 13, 2025 [3]